Mesalamine Suppository Size Reduction via Low Melting Base
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesalamine suppositories are large and have a high melting point, leading to discomfort and potential issues with content uniformity and dissolution, while existing methods for reducing size and melting point do not effectively maintain therapeutic efficacy.
Innovation Solution
The mesalamine suppository size is reduced by increasing the tap density and lowering the melting point of the suppository base, resulting in a smaller, more comfortable form with improved dissolution profiles, using a combination of mesalamine and a low melting suppository base like hard fat with a melting point of 32 to 35.5°C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the suppository size is reduced to improve comfort of use, then the melting point must be lowered, but this may adversely affect the stability and therapeutic efficacy of mesalamine
Solution Approach 1:
The patent changes the melting point parameter of the suppository base from conventional higher temperatures to a specific range of 32-35.5°C, and adjusts the drug load percentage to 35-50%, thereby achieving smaller suppository size (reduced by over 20% by weight) while maintaining therapeutic efficacy through optimized dissolution profiles
Solution Approach 2:
The patent uses composite suppository bases including hard fat (melting point 32-35.5°C) combined with other pharmaceutically acceptable excipients to create a material that provides both the required low melting point for comfort and the necessary stability for mesalamine therapeutic efficacy
2Weight of stationary object
If the suppository size is reduced by over 20% by weight, then the melting point is lowered, but this may affect the dissolution profile and content uniformity
Solution Approach 1:
The patent optimizes the drug load parameter to a specific range of 35-50% and controls the melting point parameter within 32-35.5°C, which ensures that even with reduced suppository weight, the content uniformity and dissolution profile (at least 75% dissolution within 2 hours) are maintained through precise parameter control
Solution Approach 2:
The patent applies local quality by ensuring uniform distribution of mesalamine within the suppository base matrix, creating consistent drug release characteristics throughout the reduced-size suppository volume, thereby maintaining content uniformity despite smaller overall size
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a mesalamine suppository that is at least 20% smaller by weight with a lower melting point, maintaining or improving therapeutic efficacy and comfort of use, and achieving rapid dissolution of at least 75% of mesalamine within 2 hours.
Implementation Method 1
lowering the melting point of the suppository base... hard fat with a melting point of 32 to 35.5°C... achieving rapid dissolution of at least 75% of mesalamine within 2 hours
Data Source
AI summary
The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.